• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Bangalore , July 10

Opto Circuits (India) Ltd's wholly-owned subsidiary, EuroCor in Germany, has received CE (Communité European) Mark approval for marketing its new polymer-free Paclitaxel-eluting coronary stent system called Taxcor-I.

This product, which is used in Coronary Angioplasty (Percutaneous Transluminal Coronary Angioplasty), is a second-generation innovation of EuroCor's present blockbuster DES (drug-eluting stent) product — Taxcor.

Mr Vinod Ramnani, Chairman and Managing Director of Opto Circuits, said, "Polymeric drug carriers, coated on the stents, have been known to cause blood clot formations, also leading to late thrombotic complications. EuroCor is the first manufacturer of a drug-eluting coronary stent system, which uses a new, polymer-free drug attachment technology. Taxcor-I considerably enhances patient safety and completely eliminates any polymer-related late adverse effects unlike many other drug eluted stent offerings from global giants.''

More Stories on : Standards & Benchmarks | Medical & Surgical Equipments

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Prajay Engineers allots shares

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line